All In Biotech

Drug Trial Radar · NCT05206890

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Jan 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

490

Planned (sponsor's estimate)

Start

Jan 14, 2022

Primary completion

Dec 31, 2026

Study completion Dec 31, 2032

Sponsor

Lead sponsor
Tongji HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
First Hospital of China Medical University; Cancer Hospital of Xinjiang Medical University; First Affiliated Hospital Xi'an Jiaotong University; Qingyuan People's Hospital; Zhejiang University; Panzhihua Central Hospital; Liangshan First People's Hospital; Guang'an people's hospital of Sichuan province; Affiliated Hospital of North Sichuan Medical College; Cancer Hospital of Guizhou Province; Guizhou International General Hospital; Yichang Central People's Hospital; Wuhan Fourth Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
First posted
Jan 25, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of fluzoparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment, and preliminarily evaluate the pharmacoeconomic of fluzoparib in the treatment of ovarian cancer.

Conditions

  • Ovarian Cancer

Interventions

  • fluzoparib monotherapy or combination therapyDrug

    patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. incidence of ≥ grade 3 Hematology related adverse event according to NCI CTCAE v5.0Time frame: 30 days after the last dose of fluzoparib

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.